Why Vor Biopharma Inc.’s (VOR) Stock Is Up 6.87%
As of Wednesday, September 30, Vor Biopharma Inc.’s VOR share price has surged by 6.87%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Vor Biopharma Inc.’s (VOR) Stock Is Down 5.42%
As of Thursday, September 24, Vor Biopharma Inc.’s VOR share price has dipped by 5.42%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Vor Biopharma Inc.’s (VOR) Stock Is Down 6.57%
As of Wednesday, September 23, Vor Biopharma Inc.’s VOR share price has dipped by 6.57%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Vor Biopharma Inc.’s (VOR) Stock Is Up 7.95%
As of Tuesday, September 22, Vor Biopharma Inc.’s VOR share price has surged by 7.95%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Vor Biopharma Inc.’s (VOR) Stock Is Up 5.09%
As of Monday, September 14, Vor Biopharma Inc.’s VOR share price has surged by 5.09%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | VOR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,111.1 | $240.6 | 47% |
|
| Shares Out (Mil) | 54.3 | 54.0 | 49% |
|
| Institutional Ownership | 96.9% | 93.1% | 71% |
|
| Float (Mil) | 37.2 | 41.4 | 40% |
|
| Beta | 1.72 | 0.95 | 87% |
|
| Avg Daily Volume (000s) | 944 | 604 | 68% |
|
| Price Change (52-week) |
(47.4%) | 49.2% | 20% |
|
| Growth | VOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (74.3%) | (10.1%) | 4% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (61.9%) | (15.7%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 4 | |
| Current EPS | ($0.720) | ($6.530) | ($3.815) | |
| Month Ago EPS | ($0.720) | ($6.530) | ($3.812) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 2 | |
| Three Months Ago EPS | ($0.768) | ($6.901) | ($3.742) | |
| Year/Year Chg | (37.8%) | (90.7%) | (94.2%) | |
| Financials | VOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | $628 | ($44) | 81% |
|
| EPS (TTM) | $20.192 | ($1.600) | 98% |
|
| Operating Cash Flow (TTM) (Mil) | ($140) | ($34) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($85) | $2 | 16% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | $932 | $175 | 40% |
|
| Valuation | VOR | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.30 | na |
|
| P/E | 0.9 | 19.1 | 1% |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | VOR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | 182.9% | (47.6%) | 100% |
|
| ROE | (73.6%) | (54.9%) | 12% |
|
| Liabilities to Assets | 141.6% | 29.3% | 98% |
|
| F-Score | 3 | 3 | 18% |
|
Vor Biopharma Inc. did not pass any screens on 10/7/2026.
